Aviron Message Board - Msg: 10506353

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron

AVIR 3.265

+0.5%

3:12 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gerald Walls who wrote (491)	7/14/1999 2:57:00 PM
From: Cacaito	Read Replies (1) of 645

pharmacology.miningco.com This could be exerting some effect on AVIR party. Also the Convertibles at $35, makes this a kind of a ceiling (my speculation, I do not fully understand this convertible business). Since Relenza will be out sooner (if FDA approved) and FluMist is taken longer than expected. There were four "bridging" studies (some ongoing?): 1. Children with asthma, 2. General population children (school settings, 3 years duration?) 3. Adults (just published) 4. Seniors (combined regular IM, with nasal, due to poor IM response). All by recollections please confirm your facts.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next